Lipigon Pharmaceuticals AB announced positive safety results from multiple dosing in the phase I trial with the drug candidate Lipisense. The drug candidate is being developed for treating hypertriglyceridemia. Lipisense is a drug candidate developed to lower blood lipid triglycerides in patients with severely elevated levels by preventing the production of the protein ANGPTL4 in the liver.

Phase I trials started in May 2022, and today, Lipigon announced additional safety results from multiple dosing showing a good safety profile for the drug candidate Lipisense in the ongoing trial. The current safety data includes the completed 6 and 12 mg multiple ascending doses (MAD) cohorts. Based on the recommendation from the safety committee, Lipigon decided to progress with a 36 mg MAD cohort.

Altogether four groups with 32 persons can be studied in the MAD cohorts. In the single ascending dose (SAD) groups, and as reported previously, the investigational drug also demonstrates a favorable safety profile. In a previous press release, Lipigon announced positive safety results for a 36 mg dosage in the SAD part.

Now, the company can report similar safety results for a dosage of 72 mg. Since no serious adverse effects and only mild reversible adverse effects related to treatment were reported, the company has also decided to include a 144 mg dose group in the SAD study. This group will be tested and analyzed in parallel with the remaining groups of the MAD study.